Related Experiment Video
Updated: Sep 10, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
KRAS: the Achilles' heel of pancreas cancer biology
Kristina Drizyte-Miller1, Taiwo Talabi2, Ashwin Somasundaram1,2
1Lineberger Comprehensive Cancer Center.
Abstract:
The genetic landscape of pancreatic ductal adenocarcinoma (PDAC) is well-established and dominated by four key genetic driver mutations. Mutational activation of the KRAS oncogene is the initiating genetic event, followed by genetic loss of function of the CDKN2A, TP53, and SMAD4 tumor suppressor genes. Disappointingly, this information has not been leveraged to develop clinically effective targeted therapies for PDAC treatment, where current standards of care remain cocktails of conventional cytotoxic drugs. Nearly all (~95%) PDAC harbors KRAS mutations, and experimental studies have validated the essential role of KRAS mutation in PDAC tumorigenic and metastatic growth. Identified in 1982 as the first gene shown to be aberrantly activated in human cancer, KRAS has been the focus of intensive drug discovery efforts. Widely considered "undruggable," KRAS has been the elephant in the room for PDAC treatment. This perception was shattered recently with the approval of two KRAS inhibitors for the treatment of KRASG12C-mutant lung and colorectal cancer, fueling hope that KRAS inhibitors will lead to a breakthrough in PDAC therapy. In this Review, we summarize the key role of aberrant KRAS signaling in the biology of pancreatic cancer; provide an overview of past, current, and emerging anti-KRAS treatment strategies; and discuss current challenges that limit the clinical efficacy of directly targeting KRAS for pancreatic cancer treatment.
Insights
Pancreatic cancer (PDAC) treatment lags due to KRAS mutations. Recent KRAS inhibitor approvals offer hope for targeted therapies against this challenging cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is characterized by four key genetic drivers, with KRAS mutations initiating tumorigenesis.
- Despite extensive research, targeted therapies for PDAC remain limited, with cytotoxic drugs as the standard of care.
- KRAS mutations are nearly ubiquitous in PDAC, highlighting their critical role in cancer progression.
Purpose of the Study:
- To review the critical role of aberrant KRAS signaling in pancreatic cancer biology.
- To provide an overview of current and emerging anti-KRAS treatment strategies.
- To discuss challenges hindering the clinical efficacy of KRAS-targeted therapies in PDAC.
Main Methods:
- Literature review of genetic drivers in PDAC.
- Analysis of KRAS mutation prevalence and functional significance.
- Examination of historical, current, and novel anti-KRAS therapeutic approaches.
- Discussion of clinical challenges and future directions for KRAS-targeted PDAC treatment.
Main Results:
- KRAS mutations are the primary initiating event in ~95% of PDAC cases.
- KRAS has historically been considered 'undruggable', hindering targeted therapy development.
- Recent approvals of KRAS inhibitors for other cancers provide a new paradigm for PDAC treatment.
Conclusions:
- Aberrant KRAS signaling is central to PDAC pathogenesis and progression.
- Targeting KRAS represents a promising avenue for novel PDAC therapies.
- Overcoming current clinical challenges is crucial for realizing the full potential of KRAS inhibitors in PDAC.
More Related Videos
08:16Mimicking and Manipulating Pancreatic Acinar-to-Ductal Metaplasia in 3-dimensional Cell Culture
Published on: February 11, 2019
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
01:16Cells and Secretions of the Pancreas
Exocrine function is carried out by acinar cells, organized into clusters known as acini. These cells contribute to digestion by releasing substantial quantities of enzyme-rich, alkaline digestive juices.
Concurrently, the dispersed clusters of endocrine cells throughout the...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...